And while it has been shown that EBP50 can cluster with EGFR, PDGFR, and the tumor suppressor NF2 to halt cell signaling and hence cancer progression[11,22-24], others have posited that EBP50's PDZ domains may actually allow for new tumor-specific interactions[4]. This evidence concerns the gene NHERF1 and neoplasm.